Premium
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Author(s) -
Winter Jordan M.,
Yeo Charles J.,
Brody Jonathan R.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23192
Subject(s) - medicine , biomarker , pancreatic cancer , pancreatic ductal adenocarcinoma , oncology , predictive value , adenocarcinoma , cancer , biochemistry , chemistry
Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15–22. © 2012 Wiley Periodicals, Inc.